Fig. 1 · Structure

Documents & Downloads

Amentoflavone

Cat. No. A12017 CAS 1617-53-4
Amentoflavone inhibits vascularization of tumors by blocking the activity of angiogenic VEGFs.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 8.36 μM Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay [PMID: 29921475]
Calu-1 IC50 > 100 μM Cytotoxicity against human Calu1 cells after 3 days [PMID: 10843573]
Fibroblast IC50 1.8 μM Inhibition of UVB irradiation-induced MMP1 production in human dermal fibroblasts after 48 hrs [PMID: 18029185]
HCT-15 IC50 > 50 μM Cytotoxicity against human HCT15 cells assessed as cell viability after 24 hrs by MTT assay [PMID: 23206866]
HeLa IC50 > 100 μM Cytotoxicity against human HeLa cells after 3 days [PMID: 10843573]
HeLa IC50 46.4 μM Cytotoxicity against human HeLa cells assessed as growth inhibition by sulforhodamine B assay [PMID: 26722868]
HeLa IC50 5.3 μM Antiproliferative activity against human HeLa cells after 48 hrs by CCK8 assay [PMID: 29475587]
HepG2 IC50 > 50 μM Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay [PMID: 23206866]
HepG2 IC50 9.13 μM Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay [PMID: 29921475]
HL-60 IC50 > 50 μM Cytotoxicity against human HL60 cells assessed as cell viability after 24 hrs by MTT assay [PMID: 23206866]
HL-60 IC50 51.2 μM Antiproliferative activity against human HL60 cells after 48 hrs by CCK8 assay [PMID: 29475587]
Huh-7 CC50 > 50 μM Cytotoxicity against human Huh7.5.1 cells by MTT assay [PMID: 22445328]
Jurkat IC50 > 50 μM Cytotoxicity against human Jurkat cells assessed as cell viability after 24 hrs by MTT assay [PMID: 23206866]
K562 IC50 > 100 μM Cytotoxicity against human K562 cells after 3 days [PMID: 10843573]
MCF7 IC50 75.4 μM Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay [PMID: 34875389]
MGC-803 IC50 9.86 μM Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 48 hrs by MTT assay [PMID: 29921475]
Monocyte IC50 3 μM Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs [PMID: 8882428]
Neutrophil IC50 0.75 μM Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pretreated for 5 mins followed by fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate [PMID: 29381070]
Neutrophil IC50 1.01 μM Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation pretreated for 5 mins followed by cytochalasin B addition for 3 mins and subsequent fMLP stimulation for 10 mins by superoxide dismutase [PMID: 29381070]
PBMC IC50 35 μM Cytotoxicity against uninfected PHA-stimulated human PBMC assessed as thymidine incorporation after 24 hrs by trypan blue exclusion method [PMID: 9322359]

20 records · Scroll to view more

Amentoflavone Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of Amentoflavone from 2 published references. In vitro models include SARS-CoV 3CLpro.

Amentoflavone In Vitro Studies

Amentoflavone was evaluated against SARS-CoV 3CLpro for 60 min at room temperature. The reported IC50 was 8.3 ± 1.2 μM. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Enzyme Activity in SARS-CoV 3CLpro

Cell-based study · SARS-CoV 3CLpro [1]

Amentoflavone was tested against SARS-CoV 3CLpro for 60 min at room temperature. The reported IC50 was 8.3 ± 1.2 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IC50 values of compounds represent the concentration that caused 50% enzyme activity lossIC50 8.3 ± 1.2 μM[1]

Literature-Reported Treatment Conditions

Exposure duration
60 min at room temperature
Reported limits
Not stated in the sentences used: dose, route, vehicle.
Methods and source locations

Compound reported in the paper: Amentoflavone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > SARS 3C-like protease (3CLpro) inhibition assay (S33, S34, S35, S36); Figure 5 legend (S60); Table 2 legend (S66); Table 2 (T2.h1, T2.r1)

IC50 values of compounds represent the concentration that caused 50% enzyme activity loss: IC50 values of compounds represent the concentration that caused 50% enzyme activity loss; comparator: control (enzyme, buffer, and substrate) — Table 2 legend (S66); Table 2 (T2.h1, T2.r1)

Amentoflavone In Vivo Studies

In Kunming mice with status epilepticus, Amentoflavone was administered intragastrically at 25 mg/kg for 3 consecutive days, once a day, prior to pilocarpine injection. The NO and prostaglandin E2 readouts showed significantly decreased production compared to the non-treated epilepsy group (P < 0.01). [2]

Reduced NO Production in Mice With Status Epilepticus

Animal study · Kunming mice (male, 28–32 g, 5–6 weeks old); amentoflavone pre-treated group (n = 30); mice with status epilepticus [2]

Kunming mice with status epilepticus received Amentoflavone intragastrically at 25 mg/kg for 3 consecutive days, once a day, prior to pilocarpine injection. NO production was significantly decreased compared to the non-treated epilepsy group (P < 0.01).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
NO productionReported result 25 mg/kg amentoflavone for 3 consecutive days, once a day, prior to pilocarpine injection: significantly decreased NO and prostaglandin E2 production compared to the non-treated epilepsy group (P < 0.01).[2]

Conditions shared by the study groups

Route
intragastrically
Treatment course
for 3 consecutive days, once a day, prior to pilocarpine injection
Vehicle
gum acacia solution (1%)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Amentoflavone 25 mg/kgnon-treated epilepsy group25 mg/kg amentoflavone for 3 consecutive days, once a day, prior to pilocarpine injection: significantly decreased NO and prostaglandin E2 production compared to the non-treated epilepsy group (P < 0.01).[2]
Amentoflavone 25 mg/kg
Model: Kunming mice (male, 28–32 g, 5–6 weeks old); amentoflavone pre-treated group (n = 30); mice with status epilepticus
Methods and source locations

Compound reported in the paper: Amentoflavone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animals (S1); Materials and Methods > Establishment of mouse kindling models and drug administration (S8, S10, S14, S15, S16); Materials and Methods > Nitrite measurement, prostaglandin E2, and cytokine assays (S69); Results > Effects of amentoflavone on NO and prostaglandin E2 production in the hippocampus of mice with status epilepticus (S103); Figure 6 legend (S142)

NO production: NO production; comparator: non-treated epilepsy group — Materials and Methods > Establishment of mouse kindling models and drug administration (S10); Results > Effects of amentoflavone on NO and prostaglandin E2 production in the hippocampus of mice with status epilepticus (S103)

Amentoflavone 25 mg/kg · Materials and Methods > Establishment of mouse kindling models and drug administration (S10); Results > Effects of amentoflavone on NO and prostaglandin E2 production in the hippocampus of mice with status epilepticus (S103)

Reduced Prostaglandin E2 Production in Mice With Status Epilepticus

Animal study · Kunming mice (male, 28–32 g, 5–6 weeks old); amentoflavone pre-treated group (n = 30); mice with status epilepticus [2]

Kunming mice with status epilepticus received Amentoflavone intragastrically at 25 mg/kg for 3 consecutive days, once a day, prior to pilocarpine injection. Prostaglandin E2 production was significantly decreased compared to the non-treated epilepsy group (P < 0.01).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
prostaglandin E2 productionReported result 25 mg/kg amentoflavone for 3 consecutive days, once a day, prior to pilocarpine injection: significantly decreased NO and prostaglandin E2 production compared to the non-treated epilepsy group (P < 0.01).[2]

Conditions shared by the study groups

Route
intragastrically
Treatment course
for 3 consecutive days, once a day, prior to pilocarpine injection
Vehicle
gum acacia solution (1%)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Amentoflavone 25 mg/kgnon-treated epilepsy group25 mg/kg amentoflavone for 3 consecutive days, once a day, prior to pilocarpine injection: significantly decreased NO and prostaglandin E2 production compared to the non-treated epilepsy group (P < 0.01).[2]
Amentoflavone 25 mg/kg
Model: Kunming mice (male, 28–32 g, 5–6 weeks old); amentoflavone pre-treated group (n = 30); mice with status epilepticus
Methods and source locations

Compound reported in the paper: Amentoflavone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animals (S1); Materials and Methods > Establishment of mouse kindling models and drug administration (S8, S10, S14, S15, S16); Results > Effects of amentoflavone on NO and prostaglandin E2 production in the hippocampus of mice with status epilepticus (S103); Figure 6 legend (S142)

prostaglandin E2 production: prostaglandin E2 production; comparator: non-treated epilepsy group — Materials and Methods > Establishment of mouse kindling models and drug administration (S10); Results > Effects of amentoflavone on NO and prostaglandin E2 production in the hippocampus of mice with status epilepticus (S103)

Amentoflavone 25 mg/kg · Materials and Methods > Establishment of mouse kindling models and drug administration (S10); Results > Effects of amentoflavone on NO and prostaglandin E2 production in the hippocampus of mice with status epilepticus (S103)

Specifications

Manufacturer Adooq Bioscience
CAS Number 1617-53-4
Formula C30H18O10
Molecular Weight 538.46
Synonyms Didemethyl-ginkgetin
SMILES
C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C(=C(C=C3O)O)C4=C(C=CC(=C4)C5=CC(=O)C6=C(C=C(C=C6O5)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 93 mg/mL (172.71 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Amentoflavone Research References

  1. [1] Ryu YB, Jeong HJ, Kim JH, et al. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition. Bioorg Med Chem (2010). PMID: 20934345 DOI: 10.1016/j.bmc.2010.09.035 Source material
  2. [2] Zhang Z, Sun T, Niu JG, et al. Amentoflavone protects hippocampal neurons: anti-inflammatory, antioxidative, and antiapoptotic effects. Neural Regen Res (2015). PMID: 26330838 DOI: 10.4103/1673-5374.160109 Source material

Added to your cart

View Cart Checkout
Loading...